Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to DTG/3TC from B/F/TAF in Older Persons with HIV in Kenya
NCT06444620Phase 3Completed
- Sponsor
- University of Nairobi
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir, lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Nairobi. Started Jul 2024; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06444620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444620.